Takeda admits running bad ads

Share this article:

Takeda's chief executive admitted that his company used “inappropriate expressions” in promotions of its blood pressure drug Blopress, reports the Wall Street Journal. The Journal notes that the CEO's statement comes after Japan's health ministry said it was going to examine the company's advertisements which used a graph that did not align with clinical trial results that compared Blopress and Pfizer's Norvasc.

The Journal says the company also “admitted using expressions in its ads that could potentially lead to misunderstanding that Takeda's drug was more effective than the rival product.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies